Peter F. Searle

4.7k citations

71 papers · 3.9k indexed · h-index 34

Molecular Biology top 5%
Genetics top 1%
Nutrition and Dietetics top 1%
Health, Toxicology and Mutagenesis top 1%
Oncology top 5%

Co-authors: Gary W. Stuart Richard D. Palmiter R D Palmiter Lawrence S. Young Vivien Mautner Eva I. Hyde Scott A. White Ralph L. Brinster
Topics: Virus-based gene therapy research (35 papers)Cancer Research and Treatments (23 papers)CAR-T cell therapy research (16 papers)
Cited by: Nutrition and Dietetics Biotechnology Health, Toxicology and Mutagenesis
Journals: Nature Cell Proceedings of the National Academy of Sciences
Partner nations: United Kingdom United States Australia

In The Last Decade

Peter F. Searle

69 papers receiving 3.7k citations

Peers

Countries citing papers authored by Peter F. Searle

Since Specialization

Citations

This map shows the geographic impact of Peter F. Searle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter F. Searle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter F. Searle more than expected).

Fields of papers citing papers by Peter F. Searle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter F. Searle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter F. Searle. The network helps show where Peter F. Searle may publish in the future.

Co-authorship network of co-authors of Peter F. Searle

This figure shows the co-authorship network connecting the top 25 collaborators of Peter F. Searle. A scholar is included among the top collaborators of Peter F. Searle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter F. Searle. Peter F. Searle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structure and Dynamics of Three Escherichia coli NfsB Nitro-Reductase Mutants Selected for Enhanced Activity with the Cancer Prodrug CB1954 2023 ·International Journal of Molecular Sciences ·(unknown),Andrew J. Christofferson,J. L. Ross Anderson,(unknown),A. Evans,Peter F. Searle,Scott A. White,Eva I. Hyde	2
2	How not to run out of oxygen: Primary FRCA forcibly put into practice by COVID-19 to maintain patient safety 2021 ·Journal of Patient Safety and Risk Management ·(unknown),(unknown),(unknown),(unknown),Peter F. Searle,Stephen Fenlon,(unknown)	0
3	Human Leukocyte Antigen (HLA) A1101-Restricted Epstein-Barr Virus–Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma 2015 ·Cancer Immunology Research* ·Yong Zheng,Greg Parsonage,Xiaodong Zhuang,Lee R. Machado,(unknown),(unknown),Peter F. Searle,Edwin P. Hui,Anthony T.�C. Chan,Steven P. Lee	28
4	Long-term proliferation of functional human NK cells, with conversion of CD56dim NK cells to a CD56bright phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12 2011 ·Cancer Immunology Immunotherapy ·Alexander C. Dowell,(unknown),Rupesh I. Bhatt,Steven P. Lee,Peter F. Searle	28
5	CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus 2010 ·Molecular Cancer ·(unknown),Peter F. Searle,Iain A. McNeish,Lawrence S. Young,Daniel H. Palmer	14
6	Minimal RB-responsive E1A Promoter Modification to Attain Potency, Selectivity, and Transgene-arming Capacity in Oncolytic Adenoviruses 2010 ·Molecular Therapy ·Juan J. Rojas,Sònia Guedan,Peter F. Searle,Jordi Martínez‐Quintanilla,(unknown),Francisca Alcayaga‐Miranda,Manel Cascalló,Ramón Alemany	61
7	Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: Effects of combining beneficial single mutations 2009 ·Biochemical Pharmacology ·Mansooreh Jaberipour,(unknown),Christopher P. Guise,Jane I. Grove,Richard J. Knox,Longqin Hu,Eva I. Hyde,Peter F. Searle	27
8	A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase with CB1984 2009 ·Molecular Therapy ·Prashant Patel,(unknown),Vivien Mautner,(unknown),Sarah Bonney,(unknown),Stuart I. Collins,Peter F. Searle,Diana Hull,Elizabeth Peers,John Chester,D. Michael A. Wallace,Alan Doherty,Hing Y. Leung,Lawrence S. Young,Nicholas D. James	92
9	Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo 2007 ·Gene Therapy ·Christine L. White,(unknown),Katie Twigger,Peter F. Searle,Shreerang Bhide,Richard G. Vile,Alan Melcher,H. Pandha,Kevin J. Harrington	15
10	Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells 2007 ·International Immunology ·Mojtaba Habibagahi,Thanh G. Phan,Peter F. Searle	47
11	Inhibition of NF-κB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy 2005 ·Gene Therapy ·Daniel H. Palmer,Mei‐Jou Chen,Peter F. Searle,David J. Kerr,Lawrence S. Young	11
12	Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. 2003 ·University of Birmingham Research Portal (University of Birmingham) ·Jane I. Grove,Andrew L. Lovering,Christopher P. Guise,Paul R. Race,Christopher J. Wrighton,Scott A. White,Eva I. Hyde,Peter F. Searle	60
13	Adenovirus-Mediated Expression of Dominant Negative Fibroblast Growth Factor (FGF) Receptor 1 in Thyroid Cells Blocks FGF Effects and Reduces Goitrogenesis in Mice 2003 ·The Journal of Clinical Endocrinology & Metabolism ·Emma L. Davies,James D. Ramsden,Helen Cocks,Peter F. Searle,John Watkinson,Hikaru Ueno,Ann Logan,Jayne A. Franklyn,Vivien Mautner,Margaret C. Eggo	8
14	Vectors based on reducible polycations facilitate intracellular release of nucleic acids 2003 ·The Journal of Gene Medicine ·Martin L. Read,K. Helen Bremner,David Oupický,Nicola K. Green,Peter F. Searle,Leonard W. Seymour	128
15	Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression ofE. coli nitroreductase 2000 ·International Journal of Cancer ·(unknown),Nicola K. Green,Iain A. McNeish,(unknown),Vivien Mautner,Christopher J. Wrighton,Andrew Mountain,Lawrence S. Young,Rachel Kerr,Peter F. Searle	63
16	Gene therapy strategies for colon cancer 2000 ·Molecular Medicine Today ·(unknown),Rachel Kerr,Lawrence S. Young,Peter F. Searle	33
17	Production of Retroviral Vectors for Gene Therapy with the Human Packaging Cell Line FLYRD18 1999 ·Biotechnology Progress ·Patrick A. Gerin,Peter F. Searle,Mohamed Al‐Rubeai	13
18	Improved Titers of Retroviral Vectors from the Human FLYRD18 Packaging Cell Line in Serum- and Protein-Free Medium 1999 ·Human Gene Therapy ·Patrick A. Gerin,(unknown),Peter F. Searle,Mohamed Al‐Rubeai	24
19	Virus-directed enzyme prodrug therapy using retrovirally delivered E. coli nitroreductase and CB1954 1998 ·British Journal of Cancer ·Iain A. McNeish,(unknown),(unknown),Stephen M. Roberts,Rachel Kerr,Frank Friedlos,Caroline J. Springer,Peter F. Searle	2
20	Immunotherapy II: Antigens, receptors and costimulation 1996 ·Cancer and Metastasis Reviews ·Peter F. Searle,Lawrence S. Young	7

About Peter F. Searle

Peter F. Searle is a scholar working on Biotechnology, Genetics and Oncology, having authored 71 papers that have together received 3.9k indexed citations. Recurring topics across this work include Virus-based gene therapy research (35 papers), Cancer Research and Treatments (23 papers) and CAR-T cell therapy research (16 papers). The work is most often cited by research in Nutrition and Dietetics (899 citations), Biotechnology (477 citations) and Health, Toxicology and Mutagenesis (679 citations). Peter F. Searle has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Gary W. Stuart, Richard D. Palmiter, R D Palmiter, Lawrence S. Young, Vivien Mautner, Eva I. Hyde, Scott A. White, Ralph L. Brinster, Andrew L. Lovering and Thomas M. Wilkie. Their work appears in journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact